With a mission to support novel approaches to managing and preventing heart failure, the Ted Rogers Centre for Heart Research uses its Innovation Fund to propel emerging research with great potential. The 2024-25 Innovation Fund Seed Grants are currently open and you...
The Ted Rogers Centre for Heart Research is delighted to welcome Iris Cohn as the new Innovator in Genomic Translation - also recently promoted to Director of the Pharmacogenetics (PGx) Program at The Hospital for Sick Children. A trained pharmacist, Iris established...
NorthMiRs Inc., an innovative cardiovascular biotech start-up, has won $250,000 in funding from the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) PITCH 2024 competition. Since its launch in 2018, the ECHO...
Congenital heart disease (CHD) is the most commonly occurring birth anomaly. Despite a strong genetic basis, almost 90% of cases remain genetically undiagnosed. However, the surge of new technology is enabling a search for hidden gene defects not detectable on...
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
The Ted Rogers Centre is committed to enabling equitable access to quality, person-centred heart failure care. To this end, we develop digital health solutions that are precise and predictive, and empower Canadians with heart failure to stay safe and well-managed at home.
Our revolutionary technology enables continuous monitoring and proactive, remote support so that clinicians and patients can take action before symptoms worsen. “Medly” is a remote management program where patients enter their symptoms, receive real-time feedback on self-care, medications are adjusted, and clinical teams are alerted to any urgent issues that require follow up.
Medly keeps patients safe at home, guarded by specialized care for which they’d otherwise need to visit clinics.
Medly is the first telemonitoring system to be designated a Class II medical device by Health Canada. Inside University Health Network, it has proven to cut rehospitalizations by 50% and all-cause admissions by 24% for people with heart failure.
Medly is being deployed in specialty cardiac centres and primary care clinics across Ontario. Medly Therapeutics is working with institutions to see how the technology can fit in their workflows.
Any interested clinicians may reach out to the Medly team to learn more about the successful model, best practices, and details on implementation.
